{"entity":{"id":"gt-biopharma","kind":"company","name":"GT Biopharma","aka":["GT Biopharma, Inc."],"tldr":"GT Biopharma is a San Francisco company making proteins that switch on a patient's own natural killer cells, a kind of immune cell, and point them at cancer. Its two lead medicines are in early trials in leukaemia and in solid tumours.","summary":"GT Biopharma, Inc., of San Francisco, develops Tri-specific Killer Engager (TriKE) fusion proteins, licensed from work led by Jeffrey Miller at the Masonic Cancer Center of the University of Minnesota. Each binds CD16 on natural killer cells, a tumour antigen, and carries IL-15 to drive natural killer cell expansion; the company states its second-generation camelid nanobody TriKEs are 10 to 40 times more potent than the first. On its pipeline page, GTB-3650 (CD33) is in a phase 1 dose-escalation trial in relapsed or refractory CD33-expressing leukaemias and high-risk myelodysplastic syndrome (NCT06594445), and GTB-5550 (B7-H3), given under the skin, dosed its first patient in a phase 1 basket trial in solid tumours in May 2026 (NCT07541573).","asOf":"2026-11-04","links":[{"label":"SEC: GT Biopharma Form S-1, October 2026","url":"https://www.sec.gov/Archives/edgar/data/109657/000149315226046618/forms-1.htm"},{"label":"GT Biopharma: product pipeline","url":"https://www.gtbiopharma.com/product-pipeline/overview"},{"label":"Official website","url":"https://www.gtbiopharma.com/"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["nk-cell-engagers"],"targets":["cd33","b7h3"],"drugs":["gtb-3650","gtb-5550"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The October 2026 S-1 describes the TriKE platform and the University of Minnesota trial agreements but names no candidate; candidates, phases and trial numbers were read on the company's pipeline page on 4 November 2026. Neither trial has an OnCo record."],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.gtbiopharma.com/","ticker":"GTBP","stage":"public","investors":[],"funding":[]},"route":"/companies/gt-biopharma/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"nk-cell-engagers","kind":"technology","name":"NK cell engagers","route":"/technologies/nk-cell-engagers/"}],"target":[{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/"},{"id":"cd33","kind":"target","name":"CD33","route":"/targets/cd33/"}],"drug":[{"id":"gtb-3650","kind":"drug","name":"GTB-3650","route":"/drugs/gtb-3650/"},{"id":"gtb-5550","kind":"drug","name":"GTB-5550","route":"/drugs/gtb-5550/"}]}}